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Introduction
Sjögren’s syndrome (SS) is an autoimmune disorder 
aﬀ  ecting the lachrymal and salivary glands and leads to 
dry eyes and dry mouth. Due to the presence of lympho-
cytic inﬁ  ltrates in the glands and the presence of auto-
antibodies (rheumatoid factors and antibodies against 
SS-A, SS-B, muscarinic receptors and alpha-fodrin), SS 
has been regarded as a disorder that is caused by aberra-
tions in the adaptive immune system. Recent evidence 
reviewed here, however, points to a major contribution of 
the innate immune system, at least in the initiation of the 
pathogenesis of SS.
Genetic susceptibility factors of Sjögren’s 
syndrome
Th   e etiology of SS is still unclear. Since there is a familial 
aggregation of primary SS, however, genetic susceptibility 
factors have been suspected for a long time. Initially, 
HLA haplotypes were shown to be associated with 
primary SS. Later on, however, it became clear that they 
are primarily associated only with the subset of patients 
with SS-A (HLA-DRB1*15) or SS-A and SS-B antibodies 
(HLA-DRB1*03), but not with all subsets of SS. Currently, 
genome-wide association studies are being performed to 
identify the susceptibility genes of SS. So far, the genes 
IRF5 (Interferon regulatory factor-5) and STAT4 (Signal 
transducer and activator of transcription 4) have been 
convincingly identiﬁ  ed and replicated in several studies 
as susceptibility factors of primary SS independent of the 
presence of autoantibodies.
Interferon regulatory factor-5
IRF5 is a transcription factor that mediates virus- and 
IFN-induced signaling pathways. Infection of cells with 
various viruses can activate Toll-like receptors (TLRs) 
and, further downstream, IRF5 to induce IFNalpha and 
the transcription of numerous inﬂ  ammatory proteins [1]. 
IRF5-/- mice are highly vulnerable to both DNA and RNA 
viruses and infection of them was accompanied by low 
IFNalpha concentrations in the sera [2].
Th   ree studies have conﬁ  rmed an association between a 
polymorphism in the IRF5 gene and primary SS. In a 
French study [3], the IRF5 SNP rs2004640 GT or TT 
genotype was identiﬁ  ed in 87% of primary SS patients but 
in only 77% of controls (odds ratio (OR) 1.93). Th  e  IRF5
rs2004640 T allele was found on 59% of chromosomes 
from primary SS patients compared with 52% of chromo-
somes from controls (OR 1.36). In a study of patients 
from Sweden and Norway [4], a 5-bp CGGGG indel in 
the promoter of IRF5 that is adjacent to rs2004640 was 
associated with primary SS (OR 1.63). In another French 
study [5], the 5-bp CGGGG indel in the promoter of the 
IRF5 allele was conﬁ  rmed to transmit an increased risk of 
primary SS in two cohorts (odds ratio 2.0).
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of the pathogenesis of Sjögren’s syndrome, blockade of 
this cytokine may be a rational therapeutic approach.
© 2010 BioMed Central Ltd
Aspects of innate immunity in Sjögren’s syndrome
Hui Zhi Low and Torsten Witte*
REVIEW
*Correspondence: witte.torsten@mh-hannover.de
Clinic for Immunology and Rheumatology, Medical School Hannover, 
Carl-Neuberg-Str. 1, 30625 Hannover, Germany
Low and Witte Arthritis Research & Therapy 2011, 13:218 
http://arthritis-research.com/content/13/3/218
© 2011 BioMed Central LtdTh  e CGGGG indel polymorphism of IRF5 is also 
associated with other autoimmune disorders, such as sys-
temic lupus erythematosus (SLE) [6,7], rheumatoid 
arthritis [8], and inﬂ  ammatory bowel disease [9], suggest-
ing common pathways in the induction of autoimmune 
disorders.
In functional studies, the presence of the risk allele was 
correlated with a high level of IRF5 mRNA in both 
peripheral blood mononuclear cells (PBMCs) and salivary 
gland epithelial cells (SGECs) and with increased levels of 
mRNA transcripts of the IFN-induced genes MX1 and 
IFITM1 [5]. As further evidence for the functional impact 
of the risk allele, increased expression of IRF5 mRNA 
from a promoter containing that allele was found using a 
minigene reporter. Increased expression of IRF5 protein 
was also observed in PBMCs from SLE patients carrying 
the risk allele of the CGGGG indel [6].
Signal transducer and activator of transcription 4
Th   e STAT4 transcription factor plays a key role in signal-
ing via the IFNalpha receptor by being activated and 
translocated to the nucleus after receptor ligation [10]. 
Besides its role in type I IFN signaling, STAT4 is also 
induced by IL-12 and IL-23 production by macrophages 
and dendritic cells, and is responsible for the IL-12-
dependent activation of natural killer (NK) cells, polariza-
tion of naïve CD4+ T cells to IFNgamma-producing Th  1 
cells and the IL-23-dependent expansion of Th  17 cells. 
Th  us, STAT4 has many stimulatory eﬀ   ects on the 
immune system and may contribute to autoimmune 
responses by aﬀ  ecting the functions of both innate and 
adaptive immune cells.
Association studies of SNPs in the STAT4 gene revealed 
that the T allele of rs7574865 was more common in 
primary SS patients (on 29.6% of chromosomes) than in 
controls (on 22.3% of chromosomes) [11]. Th  e ﬁ  ndings 
were conﬁ  rmed in a cohort from Colombia and Germany, 
in which the T allele was again associated with primary 
SS (OR 1.40) [12]. Th   e C allele of the SNP rs7582694 of 
the STAT4 gene, which is in complete linkage disequili-
brium with SNP rs7574865, was associated with primary 
SS in a French cohort (OR 1.57) [13].
Polymorphism of STAT4 has also been associated with 
other autoimmune disorders. Th  e haplotype marked by 
the SNP rs7574865 was more common in SLE patients of 
European ancestry (OR 1.55) [14], in SLE patients from 
the US and Sweden (OR 1.57) [15] and in a Chinese Han 
population (OR 1.51) [16].
Th  e T allele of SNP rs7574865 was also found to be 
asso  ciated with rheumatoid arthritis [14,17], with ORs 
comparable to those observed in SLE, and, in a Spanish 
study, with susceptibility to limited cutaneous systemic 
sclerosis (OR 1.61), but not with diﬀ  use cutaneous sys-
temic sclerosis [18]. Th   ese data have been conﬁ  rmed in a 
combined meta-analysis of the Spanish cohort and ﬁ  ve 
independent cohorts of European ancestry [18].
Th  ere was no signiﬁ   cant association of any of the 
STAT4 genotypes with mRNA levels of STAT4α and 
STAT4β among 30 primary SS patients [13]. Th  ere  was, 
however, a weak correlation of STAT4 rs7574865 and 
rs7582694 polymorphisms, which are in complete linkage 
disequilibrium, with STAT4α mRNA levels in PBMCs 
from healthy donors [19]. In addition, the presence of the 
SNP correlated with increased expression of the risk 
allele of STAT4β in primary cells of mesenchymal origin 
(osteoblasts) [20].
Th   ose patients who carry all of the IRF5 and STAT4 risk 
alleles have an increased risk (OR = 6.78) for primary SS 
[4]. Th  e association of both STAT4 and IRF5 polymor-
phisms with many autoimmune diseases that are type 1 
IFN driven suggests that STAT4 and IRF5 can contribute 
to a general loss of tolerance and that IFN is also a major 
player in the induction of primary SS.
TREX-1
Recently, mutations in the TREX-1 gene (which encodes 
the most abundant 3’-5’ DNA exonuclease in cells [21]) 
have been found to be tightly linked with the develop-
ment of autoimmune diseases, including primary SS. 
Loss of function mutations of the human TREX-1 gene 
cause Aicardi-Goutieres syndrome [22], which presents 
as severe encephalitis in infants, a disorder resembling a 
congenitally acquired viral infection. Patients with 
Aicardi-Goutieres syndrome have elevated levels of type 
I IFN in the cerebrospinal ﬂ  uid. Mutations in the TREX-1 
gene have also been associated with monogenic chilblain 
lupus [23] and later with SLE [24]. Most of the cases we 
contributed to the latter analysis were patients who had 
suﬀ   ered from SLE and secondary SS, and subsequent 
careful exami  na  tion of relatives of these index subjects 
revealed that several family members carrying the 
TREX-1 mutations also suﬀ  ered from primary SS (un-
pub lished  observa tions).
It has been suggested that TREX-1 mutations result in 
defective clearance of intracellular DNA, in particular 
from endogenous retroelements, which in the absence of 
functional TREX-1 induces the production of type I IFN 
and thus autoimmunity [25]. Trex-1 knockout mice die 
from inﬂ  ammatory myocarditis at an early age [26], and 
in Trex-1-deﬁ  cient mice single-stranded DNA fragments 
derived from endogenous retroelements have been 
shown to accumulate in the heart and induce myocarditis 
[25]. Th  e accumulation of single-stranded DNA in the 
absence of Trex-1 induces the production of type I IFN 
and a double knockout of Trex-1 and the type I IFN 
receptor protected mice from developing the myocarditis 
observed in the Trex-1 single knockout [23], suggesting 
that IFN has a crucial role in this model of autoimmunity.
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studies point to a major inﬂ   uence of the type I IFN 
pathway, and thus innate immunity, on the pathogenesis 
of primary SS.
IFN signature in primary Sjögren’s syndrome
As described above, the function of the susceptibility 
genes of SS suggest an important role of type I IFN in its 
pathogenesis. Indeed, two transcriptome studies docu-
mented an IFN signature in the salivary glands of patients 
with primary SS [27,28]. Using a complementary DNA 
microarray to compare gene expression proﬁ  les in minor 
salivary glands obtained from ten patients with primary 
SS and ten control subjects, there was an upregulation of 
numerous type I IFN-induced genes in primary SS [27]. 
Furthermore, global gene expression proﬁ  ling of minor 
salivary gland cells revealed that the expression of 23 
genes in the IFN pathway, including two encoding TLRs 
(TLR8 and TLR9), was signiﬁ  cantly  diﬀ  erent  between 
patients with primary SS and controls [28]. In addition, 
mRNA obtained from peripheral blood of patients with 
primary SS revealed a pattern of overexpression of IFN-
induced genes [29]. Approximately 50% of the over-
expressed genes in PBMCs from the peripheral blood of 
patients with primary SS were found to be IFN inducible.
It has been diﬃ   cult to detect elevated concentrations of 
IFN itself in the blood of patients with SS, most likely due 
to technical challenges with the commercially available 
ELISA kits. However, it was recently shown that serum 
and plasma from patients with primary SS can induce 
IFN-regulated genes in PBMCs from control donors [30]. 
In addition, higher concentrations of IFNalpha and 
IFNbeta in the serum of patients with primary SS were 
found when cell reporter assays were used, which are 
more sensitive than ELISAs [31].
Plasmacytoid dendritic cells (PDCs) are the most potent 
producers of IFNalpha, producing up to 1,000 times more 
type I IFN than other cells. Circulating PDCs express 
higher levels of the activation marker CD40 in patients 
with primary SS. Th  e number of PDCs in the blood of 
primary SS patients is reduced, but in immuno  histo-
chemistry studies these IFN-producing cells were detected 
in the salivary glands of all patients with primary SS but 
not in controls [28]. Th   ese results imply an inﬂ  ux of PDCs 
from the blood into the inﬂ  amed tissues in primary SS.
Salivary gland epithelial cells
Immunohistochemistry revealed that the lymphocytic 
inﬁ   ltrates in SS form around epithelial structures of 
aﬀ  ected organs - for example, around the glandular epi-
thelium of the exocrine glands [32]. Th   erefore, the term 
‘autoimmune epithelitis’ was suggested for primary SS 
[33] and research has focused on the role of epithelial 
cells such as the SGECs.
Evidence for the activation of SGECs has been provided 
by immunohistochemical analyses showing that they 
express MHC class I and II molecules, the costimulatory 
molecules CD80 and CD86, the adhesion receptors 
intercellular adhesion molecule (ICAM)-1 and vascular 
cell adhesion molecule, and the local production of 
various chemokines and cytokines (IL1, IL6, TNF family 
member B cell-activating factor (BAFF)). In addition, 
conjunctival epithelial cells have been found to present 
the autoantigen SS-B (La) [34]. SGECs may thus promote 
the formation of lymphoid follicles by attracting and 
activating both B and T cells.
Th  ese  ﬁ  ndings were able to be replicated in vitro after 
techniques had been developed for long-term culture of 
SGECs. Cultured SGECs produce high amounts of BAFF 
and express several TLRs [35]. In addition, SGECs have 
been found to be prone to apoptosis. Th  ey produce 
exosomes, which are of endosomal origin and derive 
from the fusion of endosomes/lysosomes with the plasma 
membrane. Exosomes contain various proteins, including 
MHC class I and II and costimulatory molecules, cyto-
skeletal proteins and chaperones, and play a role in the 
exchange of cellular material and in the transfer of 
antigens to dendritic cells. SGECs have been shown to 
contain SS-A and SS-B [36], and therefore may initiate 
the typical autoantibody response in primary SS.
It is not clear yet what factors are responsible for the 
activation of SGECs in primary SS. Intriguingly, the signs 
of activation of SGECs, such as upregulation of MHC 
class I molecules, costimulatory molecules, TLRs and 
BAFF, remain stable even after long-term culture, 
demonstrating that these cells are intrinsically activated. 
Whether or not the activating stimulus is a virus remains 
unknown so far. SGECs appear to be the initially 
activated cells in the pathogenesis of SS and other cell 
types, such as PDCs, or components of the adaptive 
immune system are activated subsequently via the 
presentation of autoantigens or transfer of exosomes.
Pattern recognition receptors
Th   e cellular part of the immune system consists of natural 
killer cells, monocytes, macrophages, granulocytes, 
dendritic cells and mast cells. Th   e innate immune system 
responds to antigens in an HLA class II-independent 
manner. According to the danger model [37], an inﬂ  am-
matory response is initiated by conserved molecular 
patterns that may be associated with both foreign 
antigens and cellular components released by damaged 
cells. In order to recognize the molecular patterns, cells 
of the innate immune system express receptors able to 
detect highly conserved pathogen-associated molecular 
patterns (PAMPs), endogenous components released 
from damaged cells (danger associated molecular patterns 
(DAMPs)), also referred to as alarmins [38], and the loss 
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DAMPs and PAMPs are termed pattern recognition 
receptors (PRRs). So far, several PRRs have been 
characterized, in particular TLRs, retinoic acid inducible 
gene (RIG) I-like receptors and NOD-like receptors. 
TLRs primarily bind to PAMPs in the extracellular space 
and in endosomes: for example, TLR3 to viral double-
stranded RNA, TLR4 to lipopolysac  charide, TLR7 to 
single-stranded RNA and TLR9 to unmethylated DNA. 
RIG-1 is an intracellular receptor that binds to nucleic 
acids, and NOD1 and NOD2 are activated by bacterial 
peptidoglycans.
According to the danger model, tissue stress (for 
example, cell necrosis, hypoxia, low pH), and not only 
exogenous pathogens, can produce danger signals. Th  e 
activation of antigen-presenting cells via PRRs leads to 
the upregulation of MHC class I and II and costimulatory 
molecules and to the secretion of proinﬂ  ammatory 
cytokines, such as type I IFN, by PDCs. Th  ese factors 
activate the adaptive immune system, which in turn may 
produce autoantibodies. In SS, antibodies against SS-A, 
which is complexed to hYRNA, form immune complexes 
that can bind and stimulate TLRs. Th   us, a vicious cycle 
may be initiated in which the innate and adaptive 
immune systems stimulate each other to give a perpetuat-
ing autoimmune response.
Genetic studies on the role of PRRs have revealed that 
SNPs of NOD2 are associated with Crohn’s disease 
[39,40] and Blau syndrome [41]. With regard to SS, there 
is so far evidence for a role of TLRs expressed by SGECs, 
which does not exclude a major role for other PRRs.
Role of Toll-like receptors in primary Sjögren’s 
syndrome
SGECs express TLR3 and other TLRs. In comparison to 
other cells types, TLR3 is expressed at particularly high 
levels. In addition, RT-PCR analysis and functional 
studies revealed transcriptional activation of TLR2, TLR3 
and TLR4 in cultured SGECs of patients with primary SS 
[35]. TLR3 binds double-stranded RNA of viral origin 
and its synthetic analogue poly(I:C). TLR3 ligation 
induces the production of proinﬂ  ammatory  cytokines 
and upregulates BAFF production in SGECs.
Th  e role of TLRs in the pathogenesis of SS has also 
been addressed by studies in mice. Th  e injection of 
poly(I:C), a TLR3 agonist, stimulates the production of 
type I IFN. Th  e treatment rapidly induces a temporal 
hypofunction of the salivary glands of most mice strains, 
which recover after termination of the poly(I:C) treat-
ment. Mice deﬁ  cient in IFNalpha-receptor1 are partially 
protected. In NZB/W F1 mice, however, which are prone 
to the development of a lupus-like disease, TLR3 stimu-
lation induces severe sialadenitis [42]. Th   e loss of saliva 
production precedes lymphocyte inﬁ  ltration [42]. Four 
months after the discontinuation of the innate immunity 
stimulation, a lymphocytic inﬁ   ltrate developed with 
forma  tion of lymphoid aggregates in the salivary glands. 
Th  is animal model of primary SS illustrates the initial 
sequential activation of innate immunity and the 
subsequent activation of ada  ptive immunity.
Stimulation of the adaptive immune system by 
components of innate immunity
Type I and II IFNs are the main inducers of the 
production of BAFF. Transgenic mice that overexpress 
BAFF develop polyarthritis and hallmarks of both SLE 
and SS, including inﬁ  ltrates in the salivary glands and 
reduced saliva production [43]. Th  e concentration of 
BAFF was found to be increased in the sera of patients 
with active SS [44], as well as in the salivary glands [45] 
and the saliva. Increased BAFF production was detected 
in T cells and monocytes as well as in salivary gland duct 
cells. Epithelial cells, therefore, are not only a target for 
the autoimmune response in primary SS, but also 
important in perpetuating the disease since they can 
present autoantigens and produce proinﬂ  ammatory 
cytokines, including BAFF.
Possible triggers of the IFN signature in primary 
Sjögren’s syndrome
So far, the initial inducer of IFN overproduction and the 
pathogenesis of SS has remained unclear. Th   e type I IFN 
signature would be well in line with a viral trigger of the 
disease. For example, chronic sialadenitis is associated 
with hepatitis C virus and HIV infection. Epstein-Barr 
virus, retroviruses, enteroviruses and coxsackievirus have 
been suggested to induce SS [46], even though there is 
still no deﬁ   nitive proof of their contribution to the 
disease.
O  n the other hand, the female predominance of SS 
suggests a role of hormones in its pathogenesis. In parti-
cular, a role for estrogen deprivation has been suspected, 
as the disease often starts after menopause. Estrogen-
deﬁ  cient mice develop a disease similar to primary SS 
[47]. Estrogen deﬁ  ciency induces aberrant class II MHC 
expression in exocrine glands via interactions between 
epithelial cells and PDCs. Th   e expression of MHC class II 
molecules is increased in the exocrine glands of 
ovariectomized C57BL/6 (B6) mice compared to control 
B6 mice. Th   e salivary gland dendritic cells adjacent to the 
apoptotic epithelial cells become activated. Estrogen 
deﬁ  ciency also induces the overexpression of the trans-
cription factor retinoblastoma-associated protein 48 
(RbAP48). Mice with transgenic overexpression of RbAp48 
develop autoimmune exocrinopathy resembling SS, with 
ocular and oral dryness, a lymphocytic inﬁ  ltrate in the 
salivary and lachrymal glands, and production of 
autoantibodies typical for SS (anti-SS-A, anti-SS-B, and 
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and apoptosis of epithelial cells that express MHC class II 
molecules and the costimulatory molecules CD80, CD86 
and ICAM [48].
Conclusion: current model of the pathophysiology 
of primary Sjögren’s syndrome
SS appears to be triggered by environmental factors such 
as viral infection or hypoestrogenism. In patients carry-
ing susceptibility genes predisposing to enhanced reac  tion 
of the innate immune system via IFN pathway proteins, 
epithelial cells become activated and may also produce 
IFN and other cytokines (Figure 1). Subse  quently, 
autoantigen presentation by the epithelial cells and BAFF 
overproduction induced by IFN stimulates B- and T-cell 
activation. Finally, autoantibodies against SS-A/SS-B, 
alpha-fodrin and muscarinic receptors develop as a sign 
of the involvement of the adaptive immune system.
In conclusion, there is increasing evidence that innate 
immunity, in particular the production of IFNs and the 
activation of epithelial cells via TLRs, plays a major role 
in the initiation of the pathophysiology of SS. Th  ese 
ﬁ  ndings are encouraging for future trials using anti-IFN 
antibodies as new biologicals in the treatment of primary 
SS.
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Figure 1. Current model of the initiation of the pathogenesis of Sjögren’s syndrome. (1) The disease is triggered by either a virus or 
hypoestrogenism. (2) Salivary gland epithelial cells (SGECs) become activated and start to express MHC class II molecules. (3) The subsequent 
activation of plasmacytoid dendritic cells (PDCs) induces a high production of proinfl  ammatory cytokines, including IFNalpha, in individuals with 
the risk alleles of the susceptibility genes IRF5 and STAT4. (4) Under the infl  uence of the high IFN concentration in the glands, TNF family member 
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